Once daily CRF2 peptide agonist (COR-1167)
The daily subcutaneous administration of COR-1167 with an autoinjector during the high-risk, vulnerable 3-month period after an episode of WHF bears the potential to enhance the recovery by restabilizing the patient during the decompensation phase and blocking further deterioration, therefore improving the prognosis and the quality of life of WHF patients. COR-1167 is expected to decrease left atrial pressure, central venous pressure and improve cardiac output. Clinical proof of concept has been demonstrated with urocortin-2 intravenous infusion (natural CRF2 ligand with 15 min half-life) in HF patients. Preclinical efficacy with COR-1167 (long acting peptide) has been confirmed in rat and sheep worsening heart failure models. The phase 1 single ascending dose (SAD) in healthy subjects and multiple ascending dose (MAD) have been successfully completed. Implementation of the phase 2 is underway.